BENSALEM, Pa., July 2, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Tempus AI, Inc. ("Tempus" or the "Company") (NASDAQ: TEM).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN TEMPUS AI, INC. (TEM), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 12, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of Howard G ...

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all investors who purchased or otherwise acquired securities of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims & Hers” or the “Company”) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares of Hims & Hers should contact the Firm prior to the August 25, 2025 lead pla ...

Core Viewpoint - A federal securities fraud class action against Virtu Financial Inc. has survived a motion to dismiss, and a tentative settlement has been reached with the SEC regarding allegations of inadequate disclosures to investors [1][5]. Group 1: Allegations and Legal Proceedings - The class action complaint alleges that Virtu Financial Inc. and its officers made false or misleading statements and failed to disclose deficiencies in their information access policies, overstating operational and technological efficacy [3]. - The court found that from January 2018 to April 2019, proprietary traders at Virtu could access material non-public information using widely known credentials, indicating potential reckless disregard for investor information [4]. - The court concluded that the inference of scienter, or knowledge of misleading statements, was compelling based on circumstantial evidence of the defendants' failure to inform investors about the FS Database issue [4]. Group 2: Settlement and Shareholder Actions - On July 1, 2025, the SEC and Virtu Financial Inc. announced a tentative deal to resolve the lawsuit concerning inadequate customer data protection, with settlement terms acceptable to both parties [5]. - Current shareholders who held Virtu stock since on or before November 7, 2018, can seek corporate reforms and the return of litigation defense funds at no cost [2][5].

Core Viewpoint - A class action lawsuit has been filed against DoubleVerify Holdings, Inc. for alleged securities fraud and unlawful business practices [2][3]. Company Performance - On February 28, 2024, DoubleVerify lowered its revenue growth expectations for Q1 2024, leading to a stock price drop of $8.35 per share, or 21.3%, closing at $30.89 on February 29, 2024 [3]. - On May 7, 2024, the company cut its full-year 2024 revenue outlook due to reduced ad spending from customers, resulting in a stock price decline of $11.79 per share, or 38.6%, closing at $18.78 on May 8, 2024 [4]. - On February 27, 2025, DoubleVerify reported lower-than-expected Q4 2024 sales and earnings, with a stock price drop of approximately 36%, closing at $13.90 on February 28, 2025 [5]. Market Research Findings - On March 28, 2025, Adalytics Research, LLC released a report claiming that DoubleVerify's advertisement verification services are ineffective, stating that customers are billed for ad impressions served to bots [6]. - The Wall Street Journal reported that DoubleVerify frequently fails to detect nonhuman traffic, contradicting the company's claims of helping brands avoid serving ads to bot accounts [6].

LOS ANGELES, July 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Petco Health and Wellness Company, Inc. ("Petco" or "the Company") (NASDAQ: WOOF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between January 14, 2021 and June 5, 2025, inclusive (the " ...

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, citing slow treatment timelines and high patient drop-off as contributing factors [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial performance and operational challenges [6].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Company Overview - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 and entered into transition services agreements with Labcorp [3]. Allegations - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting the transition services agreements, as well as the revenue from pre-spin projects [4]. Stock Performance - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 [5]. - On March 3, 2025, Fortrea announced disappointing financial results for Q4 and the full year 2024, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 [6].

Core Viewpoint - A lawsuit has been filed against Compass Diversified Holdings and its executives for potential violations of federal securities laws, stemming from material misstatements in financial statements related to its subsidiary, Lugano Holdings, Inc. [1][3] Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Matthews v. Compass Group Diversified Holdings, Inc., et al., No. 25-cv-981 [2] - Investors have until July 8, 2025, to request to be appointed to lead the case [2] Group 2: Financial Misstatements - Compass admitted that its fiscal 2022-2024 financial statements contained material misstatements regarding unrecorded financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable for Lugano [3] - On May 7, 2025, Compass announced that investors should not rely on its fiscal 2024 financial statements due to an ongoing internal investigation, leading to a significant stock price decline of approximately 62% from $17.25 to $6.55 per share [4] - On June 25, 2025, Compass further advised that investors should not rely on its fiscal 2022 and 2023 financial statements amid the ongoing investigation [5] Group 3: Company Background - Compass is a statutory trust that acquires and manages a group of small and middle-market businesses, including high-end jewelry designer and manufacturer Lugano Holdings, Inc. [3]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may request to be appointed to lead the case by July 11, 2025 [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID, which resumed in 2023, leading to increased acuity and utilization among Elevance's Medicaid members [3][5]. Group 3: Financial Impact and Stock Performance - Elevance had previously stated it was monitoring cost trends related to Medicaid redetermination, but the actual increase in acuity and utilization was not reflected in its financial guidance for 2024 [4][5]. - Following announcements of increased utilization and missed earnings expectations, Elevance's stock price declined significantly: a drop of $32.21 per share (nearly 6%) on July 17, 2024, and a further decline of $52.61 per share (nearly 11%) on October 17, 2024 [6][7].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and certain senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy, but allegedly misrepresented the nature of this partnership and compliance with FDA regulations [3][4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share within three days [5].